Back to List View Graph View

Androgen receptor (AR)

The androgen receptor (AR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors, encoded by the AR gene on chromosome Xq11–12.

Where the papers sit

8 papers from the last 6 months study Androgen receptor (AR) directly · updated from PubMed 15 Nov 2026

  • AR-Directed Therapeutic Strategies

    AR-directed therapy is moving beyond conventional antagonism toward degraders, transcriptional control and context-specific agonism. BMS-986365 combines ligand-directed degradation with antagonism, while other work links AR transcriptional repression of VCP to stronger oncolytic-immunotherapy effects in hepatocellular carcinoma. AR agonism is being explored in estrogen receptor-positive metastatic breast cancer, contrasting with antagonists designed for topical use and improved safety. The common goal is to exploit AR biology differently across diseases, but therapeutic context and selectivity remain open questions.

    4 papers · 50%

  • PSMA Imaging in Prostate Cancer

    PSMA imaging is being paired with androgen-directed treatment to improve staging and response interpretation in metastatic prostate cancer. Darolutamide is under study for its effect on PSMA flare, which may mimic progression on molecular imaging. Bavdegalutamide (ARV-110) is being combined with abiraterone in a phase 1b trial. The key open issue is distinguishing treatment-related flare from true disease change while defining imaging-guided clinical benefit.

    2 papers · 25%

  • AR in Neoadjuvant Breast Cancer

    AR expression is being evaluated as a prognostic marker in breast cancer treated with neoadjuvant chemotherapy. Associations with tumor grade and pathological complete response recur, but the broader conclusion is prognostic rather than predictive. AR status therefore does not yet identify who will benefit from chemotherapy. The unresolved question is whether subtype-specific AR biology can improve treatment selection beyond standard clinicopathologic factors.

    2 papers · 25%

Papers

The 8 papers from the last 6 months that study Androgen receptor (AR) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

AR-Directed Therapeutic Strategies (4)
  1. Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365. Journal of medicinal chemistry · 10 Jul 2026 PMID 42430428
  2. Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia. Journal of medicinal chemistry · 8 Jul 2026 PMID 42418259
  3. Targeting androgen receptor transcriptionally represses VCP and enhances the efficacy of oncolytic-immunotherapy in hepatocellular carcinoma. Pharmacological research · 27 Jun 2026 PMID 42364832
  4. Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. NPJ breast cancer · 17 Jun 2026 PMID 42310300
PSMA Imaging in Prostate Cancer (2)
  1. The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. BMJ open · 18 Jun 2026 PMID 42315278
  2. Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 2 Jun 2026 PMID 42227954
AR in Neoadjuvant Breast Cancer (2)
  1. Prognostic significance of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy: A retrospective cohort study. Medicine · 15 Aug 2026 PMID 42601757
  2. Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy. Future oncology (London, England) · 30 Jun 2026 PMID 42376794

By study type

Clinical trials (1)
  1. The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. BMJ open · 18 Jun 2026 PMID 42315278
Observational studies and case reports (2)
  1. Prognostic significance of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy: A retrospective cohort study. Medicine · 15 Aug 2026 PMID 42601757
  2. Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy. Future oncology (London, England) · 30 Jun 2026 PMID 42376794
Preclinical: animal, cell and lab studies (3)
  1. Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365. Journal of medicinal chemistry · 10 Jul 2026 PMID 42430428
  2. Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia. Journal of medicinal chemistry · 8 Jul 2026 PMID 42418259
  3. Targeting androgen receptor transcriptionally represses VCP and enhances the efficacy of oncolytic-immunotherapy in hepatocellular carcinoma. Pharmacological research · 27 Jun 2026 PMID 42364832
Unclassified: not yet indexed with MeSH (2)
  1. Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. NPJ breast cancer · 17 Jun 2026 PMID 42310300
  2. Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 2 Jun 2026 PMID 42227954